Abiopharma

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Companys lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silos two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimers disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silos research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore.

Additional info from NASDAQ:
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Silo focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The Companys lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Silos two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimers disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). Silos research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore.